Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Pharma shares extended gains for the fourth consecutive trading session.
At 11:25 IST, the barometer index, the S&P BSE Sensex jumped 341.41 points or 0.45% to 74,497.54. The Nifty 50 index rose 106.10 points or 0.47% to 23,044.30.
The broader market underperformed the frontline indices. The Nifty MidCap 150 Index rose declined 0.78% and the Nifty SmallCap 250 Index fell 1.44%.
The market breadth was weak. On the BSE, 961 shares rose and 2, 339 shares fell. A total of 99 shares were unchanged.
Initial Public offer (IPO)
M. K. Sons Fine Jewels received bids for 2,32,89,721 shares as against 1,19,00,000 crore shares on offer, according to stock exchange data at 11:25 IST on 29 October 2026. The issue was subscribed 1.96 times.
The issue opened for bidding on 28 October 2026 and will close on 30 October 2026. The price band of the IPO is fixed between Rs 153 and 162 per share. An investor can bid for a minimum of 91 equity shares and multiples thereof.
Bombay Coated & Special Steels received bids for 5,10,60,282 shares as against 1,65,33,012 shares on offer, according to stock exchange data at 11:25 IST on 29 October 2026. The issue was subscribed 3.09 times.
The issue opened for bidding on 29 October 2026 and will close on 2 November 2026. The price band of the IPO is fixed between Rs 78 and 82 per share. An investor can bid for a minimum of 182 equity shares and multiples thereof.
Buzzing Index:
The Nifty Pharma index jumped 1.59% to 27,136.10. The index surged 7.13% in the four consecutive trading sessions.
Laurus Labs (up 4.89%), Zydus Lifesciences (up 4.02%), Piramal Pharma (up 3.44%), Sai Life Sciences (up 2.57%) and Sun Pharmaceutical Industries (up 1.73%), Divis Laboratories (up 1.55%), Torrent Pharmaceuticals (up 1.44%), Mankind Pharma (up 1.41%), Ajanta Pharma (up 0.9%) and Gland Pharma (up 0.76%) surged.
Global Market:
Dow futures fell 107 points, signalling a negative opening for US stocks.
Asian equities came under pressure on Friday as Bank of Japan (BOJ) kept interest unchanged at 1.25%. The BOJ also upgraded its inflation forecast for its fiscal year 2027 to 2.6% from 2.4%, with the so-called “core-core” inflation forecast also raised to 2.7% from 2.6%
US stocks ended lower on Thursday, as disappointing technology earnings and concerns over AI investment returns weighed on investor sentiment. The Dow Jones Industrial Average declined 132.54 points, or 0.25%, to 52,342.56. The S&P 500 fell 23.59 points, or 0.30%, to 7,720.39, while the Nasdaq Composite dropped 365.13 points, or 1.38%, to 26,184.72.
Alphabet shares plunged 12.64% on Thursday, marking their worst daily decline on record, after its third-quarter revenue missed market expectations. Revenue increased 25% year on year to $127.58 billion, against the analyst estimate of $127.97 billion. Earnings per share stood at $2.12, below expectations of approximately $2.94.
Google Cloud revenue surged 103% to $30.7 billion, but concerns over heavy AI-related capital expenditure and the returns from these investments overshadowed the growth.
ServiceNow and Fortinet also faced heavy selling following their financial updates. Both stocks declined more than 20%, adding to pressure on the technology sector.
After the US market close, Intel shares plunged more than 17% in extended trading after the company issued a weaker-than-expected outlook. Intel reported third-quarter revenue of $16.5 billion, up 21% year on year, and non-GAAP earnings per share of $0.52. It forecast fourth-quarter revenue of $15 billion to $16 billion and non-GAAP earnings per share of $0.25.
Amazon shares fell more than 5% in extended trading despite strong cloud growth. Third-quarter net sales increased 12% to $201.94 billion, while AWS revenue rose 39% to $46 billion. Operating income increased to $28.08 billion from $17.42 billion a year earlier.
However, trailing 12-month free cash flow turned negative at $42.36 billion, compared with positive free cash flow of $14.79 billion a year earlier. Amazon maintained its 2026 capital expenditure forecast of approximately $220 billion. Its fourth-quarter revenue guidance of $240 billion to $247 billion also disappointed investors.
The US economy expanded at an annualised rate of 3.4% in the third quarter of 2026, according to the advance estimate released by the Bureau of Economic Analysis on Thursday. This compared with growth of 2.2% in the second quarter and exceeded the approximately 3% market forecast.
Consumer spending rose at a 3.8% annualised rate, while business investment also contributed to growth. Investment in information-processing equipment increased sharply, reflecting continued spending on AI-related infrastructure. The GDP figure is preliminary and subject to revision.
Meanwhile, the Personal Consumption Expenditures (PCE) price index, the Federal Reserve's preferred inflation gauge, increased 0.5% month on month in September, compared with 0.3% in August. Annual inflation accelerated to 3.6% from 3.4%.
Core PCE inflation, excluding food and energy, rose 0.3% month on month and 3.1% year on year, compared with 3.0% in August. The monthly increases were in line with market expectations.
Personal consumption expenditure increased 0.5% in September, while real consumer spending was unchanged. The data indicated that inflationary pressures remained elevated despite resilient economic growth.
Laurus Labs Ltd gained for a fifth straight session today. The stock is quoting at Rs 2374.8, up 5.83% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.72% on the day, quoting at 23102.8. The Sensex is at 74685.25, up 0.72%. Laurus Labs Ltd has risen around 19.7% in last one month.
Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has risen around 3.43% in last one month and is currently quoting at 26710.8, up 1.88% on the day. The volume in the stock stood at 54.31 lakh shares today, compared to the daily average of 16.59 lakh shares in last one month.
The benchmark November futures contract for the stock is quoting at Rs 2372.7, up 5.21% on the day. Laurus Labs Ltd is up 149.02% in last one year as compared to a 10.18% drop in NIFTY and a 22.72% drop in the Nifty Pharma index.
The PE of the stock is 139.01 based on TTM earnings ending June 26.
Galenvs is a contract research and development organization (CRO/ CDMO) specializing in custom oligonucleotide synthesis and functional magnetic-nanoparticle (MNP) technologies for the diagnostics and therapeutics markets. It operates a vertically integrated platform spanning discovery, optimization, synthesis, purification, validation and pilot-scale production.
Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 2182.3, up 1.88% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.19% on the day, quoting at 22705.75. The Sensex is at 73291.61, down 0.42%. Laurus Labs Ltd has added around 10.27% in last one month.
Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 1.54% in last one month and is currently quoting at 26267.25, up 0.96% on the day. The volume in the stock stood at 13.42 lakh shares today, compared to the daily average of 15.92 lakh shares in last one month.
The benchmark November futures contract for the stock is quoting at Rs 2190, up 2.16% on the day. Laurus Labs Ltd is up 126.92% in last one year as compared to a 12.85% fall in NIFTY and a 18.23% fall in the Nifty Pharma index.
The PE of the stock is 132.5 based on TTM earnings ending June 26.
Laurus Labs Ltd is up for a third straight session in a row. The stock is quoting at Rs 2010.1, up 2.87% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.29% on the day, quoting at 23413.6. The Sensex is at 74819.64, up 0.71%. Laurus Labs Ltd has risen around 11.61% in last one month.
Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has risen around 2.67% in last one month and is currently quoting at 26710.1, up 1.25% on the day. The volume in the stock stood at 12.69 lakh shares today, compared to the daily average of 38.3 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 2007.8, up 1.79% on the day. Laurus Labs Ltd is up 122.41% in last one year as compared to a 7.1% drop in NIFTY and a 20.91% drop in the Nifty Pharma index.
The PE of the stock is 121.07 based on TTM earnings ending June 26.
Laurus Labs Ltd is up for a third straight session in a row. The stock is quoting at Rs 1910.3, up 1.23% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.13% on the day, quoting at 24176.5. The Sensex is at 77308.83, down 0.21%. Laurus Labs Ltd has risen around 8.61% in last one month.
Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has risen around 2.95% in last one month and is currently quoting at 26626.3, up 0.52% on the day. The volume in the stock stood at 24.5 lakh shares today, compared to the daily average of 20.49 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 1887.7, up 0.37% on the day. Laurus Labs Ltd is up 121.61% in last one year as compared to a 1.32% drop in NIFTY and a 22.73% drop in the Nifty Pharma index.
The PE of the stock is 116.9 based on TTM earnings ending June 26.